EXEL Stock Overview
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Exelixis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.65 |
| 52 Week High | US$36.60 |
| 52 Week Low | US$19.20 |
| Beta | 0.51 |
| 11 Month Change | 20.90% |
| 3 Month Change | 34.41% |
| 1 Year Change | 61.16% |
| 33 Year Change | 98.23% |
| 5 Year Change | 109.11% |
| Change since IPO | 128.15% |
Recent News & Updates
Recent updates
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Oct 31Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story
Oct 31
Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching
Oct 26Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult
Sep 02Exelixis Comes Up Aces
Aug 08If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity
Jun 14It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year
May 24Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality
May 07Exelixis: With Patent Litigation Decision Due Soon, There Are Options
May 02Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease
Feb 26Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors
Dec 27An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued
May 30Shareholder Returns
| EXEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | -6.5% | -1.0% |
| 1Y | 61.2% | 14.6% | 30.3% |
Return vs Industry: EXEL exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: EXEL exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| EXEL volatility | |
|---|---|
| EXEL Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EXEL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EXEL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,310 | Mike Morrissey | www.exelixis.com |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis, Inc. Fundamentals Summary
| EXEL fundamental statistics | |
|---|---|
| Market cap | US$9.83b |
| Earnings (TTM) | US$466.92m |
| Revenue (TTM) | US$2.08b |
21.2x
P/E Ratio4.8x
P/S RatioIs EXEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXEL income statement (TTM) | |
|---|---|
| Revenue | US$2.08b |
| Cost of Revenue | US$78.00m |
| Gross Profit | US$2.00b |
| Other Expenses | US$1.54b |
| Earnings | US$466.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.64 |
| Gross Margin | 96.25% |
| Net Profit Margin | 22.43% |
| Debt/Equity Ratio | 0% |
How did EXEL perform over the long term?
See historical performance and comparison